While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates
Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family that contributes to tumour cell proliferation, adhesion, migration, differentiation, and apoptosis1. The overexpression or amplification of HER2-negatively impacts the survival of patients with both...